Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is a unique clinicopathological subtype of epithelial ovarian Cancer that is resistant to standard chemotherapy. Eribulin, a microtubule dynamics inhibitor of halichondrin class, has unique effects in the Cancer microenvironment such as induction of epithelization and reduction in metastatic potential in breast Cancer cells; however, nothing is known about the effect of eribulin and the detailed mechanisms in OCCC. This study aimed to investigate the involvement of Ferroptosis and its mechanism in the antitumor activity of eribulin in OCCC cells and a mouse xenograft model. We found that eribulin-induced cell death was reduced by Ferroptosis inhibitors; deferoxamine, an iron chelator and ferrostatin-1, a lipid peroxidation inhibitor. Eribulin increased the levels of intracellular iron, Reactive Oxygen Species (ROS), and lipid peroxides, and increased the mitochondrial membrane potential. Eribulin downregulated the expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH), and superoxide dismutase (SOD) activity. The combination of eribulin and ML210, a Glutathione Peroxidase 4-inhibiting Ferroptosis inducer, had a synergistic effect on Ferroptosis. Taken together, our findings show firstly that eribulin triggers Ferroptosis in OCCC and this effect occurs via the suppression of the Nrf2-HO-1 signaling pathway, SOD activity and the promotion of lipid peroxidation. These findings suggest that eribulin-induced Ferroptosis is associated with its anti-tumor effect and also could be a potential therapeutic target in OCCC.

Dihydroorotate dehydrogenase; Eribulin; Ferroptosis; Mitochondria; Nrf2; Ovarian clear cell carcinoma.